glioma
No description yet: the sentence for this tag has not been written. 9 records carry it: 7 people, 2 biomarkers.
Related tags
By kind
9 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
1p/19q codeletion Genome-wide readout Loss of one copy each of chromosome arms 1p and 19q, together with an IDH mutation, defines oligodendroglioma in the WHO 2021 classification. It predicts a slower course and a good response to chemotherapy, and separates oligodendroglioma from astrocytoma. | Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, Glioma & glioblastoma, Astrocytoma, IDH-mutant | none | biomarker, no-approval | ||
H3 K27M mutation H3-3A H3 K27M is a single change in a histone that defines diffuse midline glioma, including the brain-stem tumour DIPG. In 2025 dordaviprone became the first drug approved for tumours carrying it. | Diffuse midline glioma, H3 K27-altered, Paediatric high-grade glioma | none | biomarker, paediatric | ||
Ingo K. Mellinghoff Chair, Department of Neurology, Memorial Sloan Kettering Cancer Center · Memorial Sloan Kettering Cancer Center Led INDIGO, the trial that made vorasidenib the first targeted therapy for low-grade IDH-mutant glioma. | Glioma & glioblastoma | none | idh, targeted-therapy | ||
Martin J. van den Bent Professor of Neuro-Oncology, Erasmus MC Cancer Institute · Erasmus MC Cancer Institute Led the EORTC glioma trials that established chemotherapy for anaplastic gliomas and the value of 1p/19q and IDH status. | Glioma & glioblastoma | none | eortc, chemotherapy | ||
Michelle Monje Professor of Neurology and Neurological Sciences, Stanford University; HHMI Investigator · Stanford Health Care / Stanford Cancer Institute Founded cancer neuroscience and led the GD2 CAR-T trial that produced the first regressions of diffuse midline glioma. | none | none | paediatric, car-t, cancer-neuroscience | ||
Mitchel S. Berger Professor of Neurological Surgery and Director, Brain Tumor Center, UCSF · UCSF Helen Diller Family Comprehensive Cancer Center Neurosurgeon who proved that removing more of a glioma extends survival and pioneered awake mapping to do it safely. | Glioma & glioblastoma | none | surgery, neurosurgery | ||
Monika E. Hegi Professor and Head of the Laboratory of Brain Tumor Biology and Genetics, Lausanne University Hospital (CHUV) · Lausanne University Hospital (CHUV) / Ludwig Institute Lausanne Showed that MGMT promoter methylation predicts benefit from temozolomide, the biomarker every glioblastoma patient is now tested for. | Glioma & glioblastoma | none | biomarkers, mgmt | ||
Patrick Y. Wen Director, Center for Neuro-Oncology, Dana-Farber Cancer Institute; Professor of Neurology, Harvard Medical School · Dana-Farber Brigham Cancer Center Neuro-oncologist who created the RANO response criteria used in every brain tumour trial and leads glioblastoma drug development. | Glioma & glioblastoma | none | response-criteria, neuro-oncology | ||
Timothy F. Cloughesy Director, UCLA Neuro-Oncology Program · UCLA Jonsson Comprehensive Cancer Center Neuro-oncologist whose neoadjuvant PD-1 trial showed immunotherapy before surgery can activate immune responses in glioblastoma. | Glioma & glioblastoma | none | immunotherapy, neoadjuvant |
